{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-111729","form_type":"8-K","ticker":"MRK","cik":"0000310158","company_name":"Merck & Co., Inc.","filed_at":"2022-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.126626+00:00","generated_at":"2026-06-23T00:19:15.456527+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Merck Q3 beats: rev $15B, non-GAAP EPS $1.85; raises FY outlook; Davis to become Chairman","bullets":["Q3 revenue $15.0B (+14% YoY); GAAP EPS $1.28, non-GAAP EPS $1.85 (+4% from $1.78).","KEYTRUDA sales $5.4B (+20%), GARDASIL sales $2.3B (+15%); LAGEVRIO contributed $436M.","Raises FY2022 sales outlook to $58.5-59.0B (growth 20-21%); non-GAAP EPS guidance raised to $7.32-7.37.","Executive Chairman Kenneth Frazier to retire Nov 30; CEO Robert Davis elected Chairman effective Dec 1."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-111729","json":"https://secwatch.observer/filing/0001104659-22-111729.json","markdown":"https://secwatch.observer/filing/0001104659-22-111729.md","text":"https://secwatch.observer/filing/0001104659-22-111729.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/310158/000110465922111729/0001104659-22-111729-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/310158/000110465922111729/tm2227726d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T00:19:15.456527+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"37409498b03401a73d02ccc891ac20440e9afcf0","claim":"Merck & Co., Inc. updated its the third quarter of 2022 guidance (raised).","evidence_excerpt":"Incorporated by reference is a press release issued by Merck & Co., Inc. (“Merck”) on October 27, 2022, regarding earnings for the third quarter of 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/310158/000110465922111729/0001104659-22-111729-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2022"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"3186435b90","claim":"Kenneth C. Frazier departed as Executive Chairman at Merck & Co., Inc..","evidence_excerpt":"Kenneth C. Frazier, the Executive Chairman of Merck’s Board of Directors (the “Board”) will retire from the Board, effective November 30, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/310158/000110465922111729/0001104659-22-111729-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retire"},{"label":"Role","value":"Executive Chairman"}],"fact_type":"executive_change"},{"claim_id":"dec437c331","claim":"Robert M. Davis was elected as Chairman of the Board at Merck & Co., Inc..","evidence_excerpt":"the Board unanimously elected Robert M. Davis, Merck’s current Chief Executive Officer and President as well as a Director on the Board to serve as Chairman of the Board, effective December 1, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/310158/000110465922111729/0001104659-22-111729-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}